{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:03:48Z","timestamp":1766088228511,"version":"3.41.2"},"reference-count":44,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ANID-CONICYT FONDECYT","award":["1212006"],"award-info":[{"award-number":["1212006"]}]},{"name":"ANID-FONDECYT POSTDOCTORAL","award":["3200646"],"award-info":[{"award-number":["3200646"]}]},{"name":"CETREN-UC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u00a0<\/jats:title>\n                  <jats:p>A large proportion of patients with low-renin hypertension (LRH) correspond to primary aldosteronism (PA). However, some of these subjects have low to normal aldosterone. Since low renin is driven by excessive mineralocorticoids or glucocorticoids acting on mineralocorticoid receptors (MRs), we hypothesize that a low-cortisone condition, associated classically with 11\u03b2HSD2 deficiency, is a proxy of chronic MR activation by cortisol, which can also lead to low renin, elevated blood pressure, and renal and vascular alterations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate low cortisone as a predictor of low renin activity and its association with parameters of kidney and vascular damage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cross-sectional study was carried out in 206 adult subjects. The subjects were classified according to low plasma renin activity (&amp;lt;1\u2005ng\/mL \u00d7 hours) and low cortisone (&amp;lt;25th percentile).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Plasma renin activity was associated with aldosterone (r = 0.36; P &amp;lt; .001) and cortisone (r = 0.22; P = .001). A binary logistic regression analysis showed that serum cortisone per ug\/dL increase predicted the low-renin phenotype (OR 0.4, 95% CI 0.21-0.78). The receiver operating characteristic curves for cortisone showed an area under the curve of 0.6 to discriminate subjects with low renin activity from controls. The low-cortisone subjects showed higher albuminuria and PAI-1 and lower sodium excretion. The association study also showed that urinary cortisone was correlated with blood pressure and serum potassium (P &amp;lt; .05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This is the first study showing that low cortisone is a predictor of a low-renin condition. Low cortisone also predicted surrogate markers of vascular and renal damage. Since the aldosterone to renin ratio is used in the screening of PA, low cortisone values should be considered additionally to avoid false positives in the aldosterone\u2013renin ratio calculation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvae051","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T23:16:17Z","timestamp":1710371777000},"source":"Crossref","is-referenced-by-count":4,"title":["Low Cortisone as a Novel Predictor of the Low-Renin Phenotype"],"prefix":"10.1210","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-1468","authenticated-orcid":false,"given":"Alejandra","family":"Tapia-Castillo","sequence":"first","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 8330077 , Chile"},{"name":"Centro Traslacional de Endocrinolog\u00eda UC (CETREN-UC) , Santiago 8330033 , Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0668-412X","authenticated-orcid":false,"given":"Cristian A","family":"Carvajal","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 8330077 , Chile"},{"name":"Centro Traslacional de Endocrinolog\u00eda UC (CETREN-UC) , Santiago 8330033 , Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4745-6219","authenticated-orcid":false,"given":"Jorge A","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 8330077 , Chile"},{"name":"Centro Traslacional de Endocrinolog\u00eda UC (CETREN-UC) , Santiago 8330033 , Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Sandoval","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 8330077 , Chile"},{"name":"Centro Traslacional de Endocrinolog\u00eda UC (CETREN-UC) , Santiago 8330033 , Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fidel","family":"Allende","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratories, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 7820436 , Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Solari","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratories, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 7820436 , Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5500-4434","authenticated-orcid":false,"given":"Carlos E","family":"Fardella","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 8330077 , Chile"},{"name":"Centro Traslacional de Endocrinolog\u00eda UC (CETREN-UC) , Santiago 8330033 , Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"2","key":"2024040610001677800_bvae051-B1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/ijms19020546","article-title":"The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor","volume":"19","author":"Baudrand","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2024040610001677800_bvae051-B2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2265.2007.02898.x","article-title":"Diagnosis and treatment of low-renin hypertension","volume":"67","author":"Mulatero","year":"2007","journal-title":"Clin Endocrinol"},{"issue":"4","key":"2024040610001677800_bvae051-B3","first-page":"e29","article-title":"Heart disease and stroke statistics\u20132015 update: a report from the American heart association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"2024040610001677800_bvae051-B4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1161\/01.HYP.1.5.468","article-title":"Pathophysiology of hypertension in blacks and whites. A review of the basis of racial blood pressure differences","volume":"1","author":"Gillum","year":"1979","journal-title":"Hypertension"},{"issue":"4","key":"2024040610001677800_bvae051-B5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/cen.13741","article-title":"Diagnostic approach to low-renin hypertension","volume":"89","author":"Monticone","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"2","key":"2024040610001677800_bvae051-B6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","article-title":"Primary aldosteronism and hypertensive disease","volume":"42","author":"Mosso","year":"2003","journal-title":"Hypertension"},{"issue":"1","key":"2024040610001677800_bvae051-B7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2024040610001677800_bvae051-B8","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"issue":"14","key":"2024040610001677800_bvae051-B9","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2024040610001677800_bvae051-B10","doi-asserted-by":"crossref","first-page":"dgz315","DOI":"10.1210\/clinem\/dgz315","article-title":"Classic and nonclassic apparent mineralocorticoid excess syndrome","volume":"105","author":"Carvajal","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024040610001677800_bvae051-B11","first-page":"253","article-title":"Genetics of hypertensive syndrome","volume":"71","author":"Martinez-Aguayo","year":"2009","journal-title":"Horm Res"},{"issue":"52","key":"2024040610001677800_bvae051-B12","doi-asserted-by":"crossref","first-page":"E11248","DOI":"10.1073\/pnas.1716621115","article-title":"Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11beta-hydroxysteroid dehydrogenase type 2 deficiency","volume":"114","author":"Yau","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2024040610001677800_bvae051-B13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00004872-200018030-00001","article-title":"The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension","volume":"18","author":"Ferrari","year":"2000","journal-title":"J Hypertens"},{"key":"2024040610001677800_bvae051-B14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1210\/jc.2018-01197","article-title":"Clinical, biochemical, and genetic characteristics of \u201cnonclassic\u201d apparent mineralocorticoid excess syndrome","volume":"104","author":"Tapia-Castillo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024040610001677800_bvae051-B15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/01.HYP.0000038478.59760.41","article-title":"Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism","volume":"40","author":"Mulatero","year":"2002","journal-title":"Hypertension"},{"key":"2024040610001677800_bvae051-B16","first-page":"151","article-title":"[Measurement of low levels of plasma renin activity. A methodological improvement]","volume":"126","author":"Montero","year":"1998","journal-title":"Rev Med Chil"},{"issue":"6","key":"2024040610001677800_bvae051-B17","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"issue":"1","key":"2024040610001677800_bvae051-B18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12967-019-02143-8","article-title":"Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess","volume":"17","author":"Tapia-Castillo","year":"2019","journal-title":"J Transl Med"},{"key":"2024040610001677800_bvae051-B19","first-page":"1269","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2024040610001677800_bvae051-B20","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/ajh\/hpw056","article-title":"Usefulness and pitfalls in sodium intake estimation: comparison of dietary assessment and urinary excretion in Chilean children and adults","volume":"29","author":"Campino","year":"2016","journal-title":"Am J Hypertens"},{"issue":"9","key":"2024040610001677800_bvae051-B21","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/HJH.0000000000001017","article-title":"Cortisol\/cortisone ratio and matrix metalloproteinase-9 activity are associated with pediatric primary hypertension","volume":"34","author":"Martinez-Aguayo","year":"2016","journal-title":"J Hypertens"},{"issue":"2","key":"2024040610001677800_bvae051-B22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/HYPERTENSIONAHA.118.11064","article-title":"Hypertension in blacks: individualized therapy based on renin\/aldosterone phenotyping","volume":"72","author":"Spence","year":"2018","journal-title":"Hypertension"},{"issue":"9","key":"2024040610001677800_bvae051-B23","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/ajh\/hpt091","article-title":"Bimodal aldosterone distribution in low-renin hypertension","volume":"26","author":"Adlin","year":"2013","journal-title":"Am J Hypertens"},{"issue":"8","key":"2024040610001677800_bvae051-B24","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/ajh\/hpy051","article-title":"Serum cortisol and cortisone as potential biomarkers of partial 11beta-hydroxysteroid dehydrogenase type-2 deficiency","volume":"31","author":"Carvajal","year":"2018","journal-title":"Am J Hypertens"},{"issue":"6","key":"2024040610001677800_bvae051-B25","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1161\/hy1101.096112","article-title":"In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice","volume":"38","author":"Ferrari","year":"2001","journal-title":"Hypertension"},{"issue":"8563","key":"2024040610001677800_bvae051-B26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(87)91014-2","article-title":"Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age","volume":"2","author":"Stewart","year":"1987","journal-title":"Lancet"},{"issue":"2","key":"2024040610001677800_bvae051-B27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0039-128X(94)90080-9","article-title":"Apparent mineralocorticoid excess type II","volume":"59","author":"Mantero","year":"1994","journal-title":"Steroids"},{"issue":"6","key":"2024040610001677800_bvae051-B28","doi-asserted-by":"crossref","first-page":"e39791","DOI":"10.1371\/journal.pone.0039791","article-title":"Epigenetic effects of prenatal stress on 11beta-hydroxysteroid dehydrogenase-2 in the placenta and fetal brain","volume":"7","author":"Jensen Pena","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"2024040610001677800_bvae051-B29","doi-asserted-by":"crossref","first-page":"E1234","DOI":"10.1210\/jc.2015-1760","article-title":"Apparent mineralocorticoid excess by a novel mutation and epigenetic modulation by HSD11B2 promoter methylation","volume":"100","author":"Pizzolo","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024040610001677800_bvae051-B30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.atherosclerosis.2007.11.029","article-title":"Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension","volume":"199","author":"Friso","year":"2008","journal-title":"Atherosclerosis"},{"issue":"6","key":"2024040610001677800_bvae051-B31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajh.2008.152","article-title":"Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients","volume":"21","author":"Henschkowski","year":"2008","journal-title":"Am J Hypertens"},{"issue":"4","key":"2024040610001677800_bvae051-B32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/ajh\/hps080","article-title":"Age-related changes in 11beta-hydroxysteroid dehydrogenase type 2 activity in normotensive subjects","volume":"26","author":"Campino","year":"2013","journal-title":"Am J Hypertens"},{"issue":"5","key":"2024040610001677800_bvae051-B33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2265.1996.00853.x","article-title":"Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man","volume":"45","author":"Palermo","year":"1996","journal-title":"Clin Endocrinol"},{"issue":"10","key":"2024040610001677800_bvae051-B34","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/HJH.0b013e32833c206d","article-title":"Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade","volume":"28","author":"Menne","year":"2010","journal-title":"J Hypertens"},{"issue":"3","key":"2024040610001677800_bvae051-B35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.HYP.15.3.257","article-title":"Renal functional reserve and microalbuminuria in offspring of hypertensive parents","volume":"15","author":"Grunfeld","year":"1990","journal-title":"Hypertension"},{"issue":"11","key":"2024040610001677800_bvae051-B36","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1161\/01.CIR.0000158434.69180.2D","article-title":"Low-grade albuminuria and the risks of hypertension and blood pressure progression","volume":"111","author":"Wang","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"2024040610001677800_bvae051-B37","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"29","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2024040610001677800_bvae051-B38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/hc3301.092803","article-title":"Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition","volume":"104","author":"Kaikita","year":"2001","journal-title":"Circulation"},{"issue":"9","key":"2024040610001677800_bvae051-B39","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/HJH.0000000000001375","article-title":"Relationship between plasma plasminogen activator inhibitor-1 and hypertension in American Indians: findings from the strong heart study","volume":"35","author":"Peng","year":"2017","journal-title":"J Hypertens"},{"issue":"8","key":"2024040610001677800_bvae051-B40","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-7061(02)02952-7","article-title":"PAI-1 in human hypertension: relation to hypertensive groups","volume":"15","author":"Srikumar","year":"2002","journal-title":"Am J Hypertens"},{"issue":"1","key":"2024040610001677800_bvae051-B41","first-page":"336","article-title":"Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production","volume":"85","author":"Brown","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024040610001677800_bvae051-B42","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1210\/jc.2003-031545","article-title":"Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes","volume":"89","author":"Calo","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"2024040610001677800_bvae051-B43","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1161\/CIRCULATIONAHA.113.006321","article-title":"Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?","volume":"128","author":"Simon","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"2024040610001677800_bvae051-B44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/01.STR.31.1.26","article-title":"Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator\/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke","volume":"31","author":"Johansson","year":"2000","journal-title":"Stroke"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvae051\/56997542\/bvae051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/8\/6\/bvae051\/57174799\/bvae051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/8\/6\/bvae051\/57174799\/bvae051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T10:00:47Z","timestamp":1712397647000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvae051\/7629712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,4,6]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvae051","relation":{},"ISSN":["2472-1972"],"issn-type":[{"type":"electronic","value":"2472-1972"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,3,15]]},"article-number":"bvae051"}}